Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Enrique Alvarez to Adult

This is a "connection" page, showing publications Enrique Alvarez has written about Adult.

 
Connection Strength
  
 
 
0.511
  
  1. Hua LH, Brown B, Camacho E, Chinea AR, Greenberg BM, Henry RG, Houtsma E, Moreo N, Alvarez E. Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study. J Neurol. 2025 Oct 24; 272(11):725.
    View in: PubMed
    Score: 0.045
  2. Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec; 26(1):494-502.
    View in: PubMed
    Score: 0.037
  3. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170.
    View in: PubMed
    Score: 0.033
  4. Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476.
    View in: PubMed
    Score: 0.031
  5. Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262.
    View in: PubMed
    Score: 0.028
  6. Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan; 27:383-390.
    View in: PubMed
    Score: 0.028
  7. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93.
    View in: PubMed
    Score: 0.027
  8. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug; 19(9):1204-8.
    View in: PubMed
    Score: 0.019
  9. Scharf A, Cohen JA, Marrie RA, Miller AE, Waubant E, Kilbane M, Luskin E, Azevedo CJ, Dever M, Alvarez E, Calabresi PA, Chahin S, Freeman L, Nakamura K, Longbrake EE, Mowry EM, Oh J, Rodrigues PR, Ramos M, Sotirchos ES, Cutter GR, Kaisey M, Amin M, Toljan K, Illenberger N, Bilello M, Lee J, Maya M, Obusez EC, Schindler MK, Suthiphosuwan S, Ulano A, Shinohara RT, Reich DS, Solomon AJ, Sicotte NL, Sati P, Ontaneda D. Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study. Neurology. 2026 Jul 14; 107(1):e218183.
    View in: PubMed
    Score: 0.012
  10. Wong AD, Airas L, Alvarez E, Antel J, Araujo D, Bernard G, Boudjani H, Brais B, Cocozza S, Corboy JR, Fadda G, Imitola J, Lacasse MC, Longbrake EE, Macaron G, Narayanan S, Orthmann-Murphy J, Ortiz J, Shor N, Uggetti C, Venkateswaran S, Wilson N, Miller E, La Piana R. Toward a Neuroimaging Consensus for the Work-up of Adult Genetic Leukoencephalopathies on Behalf of the White Matter Rounds Network: State of Practice. AJNR Am J Neuroradiol. 2026 Jun 03; 47(6):1448-1455.
    View in: PubMed
    Score: 0.012
  11. Tallantyre EC, Planchon SM, Howard H, Mays J, Frowd N, Cohen JA, Coles A, Hersh CM, Miller DM, Dever M, Gray EH, LaRocca NG, Nakamura K, Bale C, Covey-Crump G, Alvarez E, Arun T, Brownlee WJ, Craner M, Freeman L, Frost N, Goldman MD, Gupta RK, Harding KE, Hobart J, Hutton GJ, Hyland MH, Kalra S, Kannan M, Kantarci O, Lashley D, Lily O, Mahad D, Nicholas JA, Nicholas R, Paling D, Pearson OR, Rice CM, Samudralwar R, Schmalstieg WF, Singh M, Zune The E, Weinstock-Guttman B, Zabeti A, Love TE, Gunzler DD, Liu Y, Gerry S, Evangelou N, Ontaneda D. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 Jun; 32(7):722-736.
    View in: PubMed
    Score: 0.012
  12. Robertson D, Alvarez E, Steinman L, Hartung HP, Qian P, Selmaj K, Wray S, Wynn D, Fox EJ, Mok K, Miskin HP, Xu Y, Garner CA, Cree BAC. Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis. Front Immunol. 2026; 17:1771848.
    View in: PubMed
    Score: 0.012
  13. Van Laethem D, Costers L, Miravalle A, Alvarez E, Myers B, Boster A, Al Halawani H, Dewil M, Cambron M, Grothe M, Denissen S, Bartz R, Sima D, Ribbens A, Smeets D, Nagels G. The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis. Sci Rep. 2026 May 16; 16(1).
    View in: PubMed
    Score: 0.012
  14. Apeltsin L, Asokan S, Freitas B, Karekar K, Guzman S, Alvarez E, Yu X. Multiplex Detection of Immunoglobulins Uncovers Intrathecal IgA Elevation in Multiple Sclerosis. Cells. 2026 May 10; 15(10).
    View in: PubMed
    Score: 0.012
  15. Cree BAC, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Selmaj K, Wynn D, Mok K, Rowland C, Bodhinathan K, Sportelli P, Miskin HP, Steinman L. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026 Apr 01; 83(4):348-358.
    View in: PubMed
    Score: 0.012
  16. Asokan S, Zhou W, Fringuello A, Pointon T, Kennedy A, Freitas B, Tumas French J, Zhao H, Coughlan C, Alvarez E, Yu X. CNS-compartmentalized IgG aggregates and glycosylation in multiple sclerosis contribute to oligoclonal bands and neuronal cytotoxicity. Front Immunol. 2026; 17:1689835.
    View in: PubMed
    Score: 0.012
  17. Henry M, Crompton T, Alvarez E, Enoka RM. Impaired force control and muscle activation during isometric contractions in people with multiple sclerosis. J Electromyogr Kinesiol. 2026 Apr; 87:103124.
    View in: PubMed
    Score: 0.011
  18. Ghezzi L, Kosa P, Greenwood M, Alvarez E, Freedman CL, Cross AH, Pace F, Freedman MS, Kocot J, Piccio L, Bielekova B. From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis. Ann Neurol. 2026 02; 99(2):328-340.
    View in: PubMed
    Score: 0.011
  19. Quinn CM, Rajarajan P, Gill AJ, Kopinsky H, Wolf AB, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, Kister I. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications. Neurology. 2024 Dec 10; 103(11):e210003.
    View in: PubMed
    Score: 0.011
  20. Col NF, Solomon AJ, Alvarez E, Pbert L, Ionete C, BerriosMorales I, Chester J, Kutz C, Iwuchukwu C, Livingston T, Springmann V, Col HV, Ngo LH. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool. Mult Scler Relat Disord. 2023 Dec; 80:105092.
    View in: PubMed
    Score: 0.010
  21. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588.
    View in: PubMed
    Score: 0.009
  22. Enoka RM, Almuklass AM, Alenazy M, Alvarez E, Duchateau J. Distinguishing between Fatigue and Fatigability in Multiple Sclerosis. Neurorehabil Neural Repair. 2021 11; 35(11):960-973.
    View in: PubMed
    Score: 0.008
  23. Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.008
  24. Kline PW, Christiansen CL, Hager ER, Alvarez E, Mañago MM. Movement compensations during a step ascent task are associated with stair climbing performance in people with multiple sclerosis. Gait Posture. 2021 06; 87:27-32.
    View in: PubMed
    Score: 0.008
  25. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487.
    View in: PubMed
    Score: 0.008
  26. Mañago MM, Kline PW, Alvarez E, Christiansen CL. Trunk and pelvis movement compensation in people with multiple sclerosis: Relationships to muscle function and gait performance outcomes. Gait Posture. 2020 05; 78:48-53.
    View in: PubMed
    Score: 0.008
  27. Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2020 Feb; 38:101508.
    View in: PubMed
    Score: 0.007
  28. Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498.
    View in: PubMed
    Score: 0.007
  29. Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 07 15; 332:187-197.
    View in: PubMed
    Score: 0.007
  30. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
    View in: PubMed
    Score: 0.007
  31. Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2019 Jan; 27:65-73.
    View in: PubMed
    Score: 0.007
  32. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 08 30; 379(9):846-855.
    View in: PubMed
    Score: 0.007
  33. Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging. 2018 07; 28(4):399-405.
    View in: PubMed
    Score: 0.007
  34. Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabil Neural Repair. 2018 01; 32(1):84-93.
    View in: PubMed
    Score: 0.007
  35. Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28; 89(22):2238-2244.
    View in: PubMed
    Score: 0.006
  36. Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2018 01; 38(1):44-55.
    View in: PubMed
    Score: 0.006
  37. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013 Dec; 19(14):1938-42.
    View in: PubMed
    Score: 0.005
  38. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov; 69(11):1482-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)